Dorzolamide
From DrugPedia: A Wikipedia for Drug discovery
Image:Dorzolamide-2D-skeletal.png | |
Image:Dorzolamide-3D-balls.png | |
Dorzolamide
| |
Systematic (IUPAC) name | |
2-ethylamino-4-methyl-5, 5-dioxo-5$l^{6}, 7-dithiabicyclo[4.3.0] nona-8,10- diene-8-sulfonamide | |
Identifiers | |
CAS number | 120279-96-1 |
ATC code | S01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox |
Mol. mass | 324.443 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | ~33% |
Metabolism | ? |
Half life | 4 months |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Dorzolamide is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. This drug was the first drug in human therapy (market introduction 1995) which resulted from structure-based drug design.
Trusopt (dorzolamide hydrochloride ophthalmic solution) is a carbonic anhydrase inhibitor formulated for topical ophthalmic use. Trusopt is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension. This drug was developed by University of Florida researchers.<ref>University of Florida facts</ref> The primary creator most credited with pioneering this drug was Dr. Thomas H. Maren.<ref>University of Florida News - Dr. Thomas Maren, A Founding Father Of UF’s Medical College And Renowned Basic Scientist, Dies At Summer Home In Maine</ref>
[edit] References
<references/>
[edit] Further reading
- Kubinyi H (1999). "Chance favors the prepared mind--from serendipity to rational drug design". J Recept Signal Transduct Res 19 (1-4): 15–39. PMID 10071748.
- Plummer C, MacKay E, Gelatt K. "Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs.". Vet Ophthalmol 9 (4): 245–9. doi: . PMID 16771760.
- Grover S, Apushkin M, Fishman G (2006). "Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa.". Am J Ophthalmol 141 (5): 850–8. doi: . PMID 16546110.
- Almeida G, Faria e Souza S (2006). "Effect of topical dorzolamide on rabbit central corneal thickness.". Braz J Med Biol Res 39 (2): 277–81. doi: . PMID 16470316.
Template:University of Florida Template:Pharma-stub Template:Antiglaucoma preparations and miotics